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The liver responds to estrogens and growth hormone (GH) which are critical regulators of
body growth, gender-related hepatic functions, and intermediate metabolism. The effects
of estrogens on liver can be direct, through the direct actions of hepatic ER, or indirect,
which include the crosstalk with endocrine, metabolic, and sex-differentiated functions of
GH. Most previous studies have been focused on the influence of estrogens on pituitary GH
secretion, which has a great impact on hepatic transcriptional regulation. However, there
is strong evidence that estrogens can influence the GH-regulated endocrine and meta-
bolic functions in the human liver by acting at the level of GHR-STAT5 signaling pathway.
This crosstalk is relevant because the widespread exposition of estrogen or estrogen-
related compounds in human. Therefore, GH or estrogen signaling deficiency as well as
the influence of estrogens on GH biology can cause a dramatic impact in liver physiology
during mammalian development and in adulthood. In this review, we will summarize the
current status of the influence of estrogen on GH actions in liver. A better understand-
ing of estrogen-GH interplay in liver will lead to improved therapy of children with growth
disorders and of adults with GH deficiency.
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INTRODUCTION
Growth hormone (GH) is the main regulator of somatic growth,
metabolism, and gender dimorphism in liver (LeRoith and Yakar,
2007; Lichanska and Waters, 2008; Baik et al., 2011; List et al.,
2011). GH is predominantly linked to linear growth during child-
hood, but continues to have important metabolic actions through-
out life. GH deficiency in adulthood causes a metabolic syndrome-
like phenotype (i.e., increased adiposity, decreased muscle mass,
metabolic disturbances, increased vascular complications) (Loria
et al., 2009). The absence of estrogen signaling causes similar meta-
bolic phenotype (Barros and Gustafsson, 2011). This metabolic
syndrome-like phenotype can be ameliorated by GH (LeRoith and
Yakar, 2007) or 17β-estradiol (E2) (Heine et al., 2000; Simpson
et al., 2005; Jones et al., 2007) replacement which suggests that GH
and E2 regulate overlapping cellular networks.
17β-Estradiol, a major natural estrogen in mammals, has phys-
iological actions which are not limited to reproductive organs
in both females and males (Simpson et al., 2005; Barros and
Gustafsson, 2011). The liver is a direct target of estrogens because
it expresses estrogen receptor alpha (ERα) which is connected,
among others, with lipid and glucose homeostasis (Foryst-Ludwig
and Kintscher, 2010; Barros and Gustafsson, 2011; Faulds et al.,
2012) and body growth (Vidal et al., 2000). Estrogens can mod-
ulate GH actions in liver by acting centrally, regulating pituitary
GH secretion, and, peripherally, modulating GH signaling. Most
previous studies have been focused on the influence of estrogens
on pituitary GH secretion (Kerrigan and Rogol, 1992). The sex-
specific GH secretion release from pituitary has been shown to
have a great impact on hepatic transcriptional regulation (Mode
and Gustafsson, 2006). However, there is also strong evidence that
estrogens modulate GH action at the level of GHR expression
and signaling. Particularly, E2 has been shown to induce sup-
pressor of cytokine signaling (SOCS)-2 which in turn negatively
regulates GHR-Janus kinase (JAK)-2-signal transducer and acti-
vator of transcription (STAT)-5 signaling pathway (Leung et al.,
2004; Santana-Farre et al., 2008). This phenomenon is clinically
relevant because the GHR-JAK2-STAT-5 signaling is of particular
importance in the regulation of endocrine, metabolic, and sex-
differentiated actions of GH in liver. Importantly, disruption of
GHR-JAK2-STAT5 signaling is associated with hepatic metabolic
changes that include fatty liver, fibrosis, and hepatocellular carci-
noma (Baik et al., 2011). This interplay is also relevant because
the widespread exposition of estrogen or estrogen-related com-
pounds in human (Wolthers et al., 2001). In this work, we will
summarize the multiple biological consequences that can appear
after the interplay of E2 with GH in liver. A better understanding
of estrogen-GH interplay will lead to improved therapy of children
with growth disorders and of adults with GH deficiency.
PHYSIOLOGICAL BASIS OF PITUITARY GH SECRETION
Growth hormone is a polypeptide mainly secreted from the soma-
totrophs within the anterior pituitary gland. In addition to the
pituitary, GH is produced in extra-pituitary tissues, which indi-
cates that GH has local paracrine-autocrine effects, distinct from
its classic endocrine somatotropic effects (Waters et al., 1999).
The regulation of pituitary GH secretion involves a complex
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neuroendocrine control system that includes the participation
of several neurotransmitters and the feedback of hormonal and
peripheral (metabolic) factors (Butler and Le Roith, 2001; Kaplan
and Cohen, 2007). Figure 1 shows that GH secretion from pitu-
itary gland is regulated by two major hypothalamic peptides: the
stimulatory GH releasing hormone (GHRH) and the inhibitory
hormone somatostatin (SS). The balance of these stimulating
and inhibiting peptides is in turn, indirectly, affected by many
physiological stimulators (i.e., sex hormones, nutrients, sleep, and
exercise) and inhibitors [i.e., insulin growth factor I (IGF-I), and
GH]. In addition to hypothalamic (GHRS, SS) and endocrine
(IGF-I, GH) factors, other peripheral (metabolic) factors influ-
ence pituitary GH release: free fatty acids (FFA), insulin, glucose,
amino acids, leptin, neuropeptide Y, and ghrelin. These factors
are primarily related to or derived from the metabolic status of
the organism, which is consistent with the role of GH in regulat-
ing substrate metabolism, adiposity, and growth, and appear to
coordinate the metabolic status of the organism with GH secre-
tion (Howard et al., 1996; Carro et al., 1997; Svensson et al.,
1998; Holst and Schwartz, 2006). Sex steroids are also physio-
logical regulators of pituitary GH secretion. Both neonatal and
post-pubertal sex steroids control the ability of the hypothala-
mus to drive the sexually dimorphism of pituitary GH secretion
in adulthood (Kerrigan and Rogol, 1992). Sexual dimorphism
in rodents seems to be regulated by estrogen secretion in adult
females and by androgen secretion, neonatally and during adult-
hood, in males. Neonatal exposure to testosterone imprints the
male program of neuroendocrine control of the pulsatile pituitary
GH secretion that is first seen at puberty, when the adult pat-
tern of GH secretion becomes evident, and continues throughout
adulthood. If such an androgen re-programing does not occur, the
secretion pattern will remain as the feminine pattern (continuous
GH secretion) (Mode and Gustafsson, 2006). The sexually dimor-
phic pattern of GH secretion is also seen in humans, but not as
marked as in the rat. Interestingly, depletion of liver-derived IGF-I
in male mice (i.e., the LID mice) causes a feminization of some of
the GH-regulated sexually dimorphic markers of liver functions
(Ohlsson et al., 2009). This is a consequence of losing the feed-
back effect exerted by IGF-I on the hypothalamic-pituitary system
which results in increased GH secretion, including elevated base-
line GH levels between pulses, which resemble a female pattern of
pituitary GH release.
THE CELLULAR REGULATION OF GH SIGNALING
Growth hormone mediates its intracellular effects via the GHR
which is ubiquitously expressed, especially in liver, fat, and mus-
cle. GHR belongs to type I cytokine receptor, a family of receptors
without intrinsic kinase activity (Brooks et al., 2008). GHR has an
extracellular domain which is connected to a cytoplasmic domain
via a flexible linker. The kinase JAK2 is constitutively associated
with a Box 1 region in the cytoplasmic domain of the GHR. In
the inactive state, the JAK2 catalytic domain is masked by its
pseudokinase domain. The GH molecule interacts with preformed
dimmers of identical GHR pairs, which results in a conforma-
tional change in the receptors and associated JAK2 molecules
(Brown et al., 2005). This event unmasks the catalytic domain
of JAK2 and results in activation of adjacent JAK2 molecules by
FIGURE 1 | Schematic representation of somatotropic axis. GHRH and
SS, two hypothalamic hormones, control the synthesis and release of GH
from the pituitary. GHRH is negatively (dashed lines) regulated by feedback
from blood GH and IGF-I concentrations. FFA also inhibits whereas leptin
and ghrelin stimulate GH release. Sex hormones and other factors also act
centrally to stimulate GH release. Circulating GH acts directly on many
organs to stimulate IGF-I production, with IGF-I production in the liver
providing the main source of blood IGF-I. GH also has direct effects on
many target tissues which can be independent of IGF-I action.
transphosphorylation. Activated JAK2 phosphorylates the GHR
cytoplasmic domain on tyrosine residues and subsequent JAK2-
dependent and -independent intracellular signal transduction
pathways evoke pleiotropic cell responses including changes in
gene transcription, cell proliferation, glucose and lipid metabo-
lism, or in cytoskeletal re-organization (Flores-Morales et al., 2001;
Rico-Bautista et al., 2004; Tollet-Egnell et al., 2004; Vijayakumar
et al., 2010). The main event in the GH signaling pathway is the
recruitment of members of the STAT family of transcription fac-
tors to phosphorylated tyrosine residues in the GHR intracellular
domain. Of the various STAT proteins (STAT 1–6), STAT5b has
been widely associated with GH biological actions in liver (Wax-
man and O’Connor, 2006; Baik et al., 2011); although STAT1, 3,
and 5a have also been shown to be recruited by the GHR. STAT5
phosphorylation by JAK2 results in their dissociation from the
receptor,dimerization,and translocation to the nucleus where they
modulate the transcription of target genes [e.g., IGF-I, acid labile
subunit (ALS), SOCS2, SOCS3, CIS] (Rowland et al., 2005; Vidal
et al., 2007). The STATs represent one of known pathways in GH-
induced signaling; others include the MAPK and PI3K pathways
(Figure 2).
The analysis of molecular mechanisms involved in inactiva-
tion of GHR-signaling pathways is also imperative for under-
standing GH physiology. The duration of GH-activated signals
is a critical component in relation to the biological actions of
this hormone. This is clearly illustrated in the case of hepatic
GH actions where signal duration regulates gender differences
in liver gene expression (Waxman and O’Connor, 2006). The
male pattern of pituitary GH secretion in rats is episodic with
peaks every 3–4 h and no measurable trough levels (Mode and
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FIGURE 2 | Schematic representation of signaling pathways used
by GH to regulate growth and metabolism. GH binds to a
preformed GHR dimmer which results in activation of JAK2 tyrosine
kinase bound to the receptor box 1 sequence proximal to the
membrane. Simultaneously, Src kinase is also activated. Canonical
protein-tyrosine kinase JAK2 signaling via STAT5 involves
phosphorylation of key tyrosine residues in the cytoplasmic domain
of GHR, which bind the Src homology 2 (SH2) domain of STAT5a/b,
recruiting STATs to the activated JAK2 and thus facilitating their
tyrosine phosphorylation and subsequent dimerization through their
SH2 motifs. Dimerized STAT5 translocates to the nucleus to regulate
gene transcription. STAT1 and STAT3 undergo direct tyrosine
phosphorylation by JAK2 without the requirement for receptor
binding. ERK can be activated either by SRC and/or PLCγ and Ras, or
by JAK2 via the adaptors SHC, GRB, and SOS. JNK is activated by
SRC. The PtdIns 3-kinase and the serine-threonine-protein kinase
mTOR pathway is activated by JAK2 via IRS phosphorylation. These
signaling pathways influence, directly or indirectly, transcription of
genes involved in growth and metabolism. ERK, extracellular
signal-regulated kinase; FAK, focal adhesion kinase; Grb, growth
factor receptor-bound protein; IRS, insulin receptor substrate; JAK2,
Janus kinase 2; JNK, c-Jun N-terminal kinase; MEK, dual specificity
mitogen-activated protein kinase kinase 2; mTOR, mammalian target
of rapamycin; PI3K, phosphoinositide 3-kinase; PKC, protein kinase C;
PLCγ, phospholipase Cγ; SHC, SH2-domain containing transforming
protein; SOCS, suppressor of cytokine signaling; SOS, son of
sevenless; SRC, proto-oncogene tyrosine-protein kinase Src; STAT,
signal transducer and activator of transcription.
Gustafsson, 2006). Consequently, intracellular activation of STAT5
is also episodic and periods with low GH circulating levels are
required to achieve maximal activation of STAT5. Female rats,
which exhibit a more continuous GH secretion pattern with
higher basal levels and smaller and irregular intermittent peaks
show reduced STAT5b activation compared with males (Mode
and Gustafsson, 2006). These differences in STAT5b activation
are responsible for several of the gender differences in hepatic
gene expression. The conserved control of GHR-JAK2 activa-
tion kinetic in multiple cell models emphasizes the importance
of mechanisms for desensitization of GH-dependent signaling
pathway in GH physiology (Flores-Morales et al., 2006). Stud-
ies on primary hepatocytes and several cell lines have shown that
GH-induced JAK2-STAT5b activation is transient, with maximal
activation achieved within the first 30 min of stimulation, followed
by a period of inactivation. This period is characterized by an
inability to achieve maximal JAK2-STAT5 activation by GH in the
following 3–4 h, unless GH is withdrawn from the media (Fer-
nández et al., 1998). Cell-surface levels of GHR are the primary
determinant of GH responsiveness. Transcriptional, translational,
and posttranslational level factors can influence GHR synthesis
and, thereby, regulate cell sensitivity to GH actions. These fac-
tors include nutritional status, endocrine context, developmental
stage, and, relevant to this review, estrogens. GHR cell-surface
translocation is also directly inhibited by IGF-I, likely contribut-
ing to a local feedback loop to hamper GH sensitivity (Leung
et al., 1997). Removal of cell-surface GHRs by endocytosis is
an early step in the termination of GH-dependent signaling.
GHR ubiquitination is a key control mechanism in the down-
regulation of GH signaling, modulating both GHR internaliza-
tion and proteasomal degradation. The ubiquitin ligase SOCS2
has been shown to be a key components of negative regula-
tors of GHR-JAK2-STAT5 signaling pathway (Rico-Bautista et al.,
2006; Vesterlund et al., 2011). SOCS proteins have been shown
to modify cytokine actions through a classic negative feedback
loop. In general, SOCS protein levels are constitutively low, but
their expression is rapidly induced by stimulation with differ-
ent cytokines including GH. Evidence also indicates that growth
factors (e.g., insulin), xenobiotics (e.g., dioxin, statins), and estro-
gens, can induce SOCS2 expression (Rico-Bautista et al., 2006;
Santana-Farre et al., 2008). Consequently, regulation of SOCS2
protein expression provides a mechanism for crosstalk where
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multiple factors, including estrogens can regulate the activity of
GH (Leung et al., 2004). SOCS2 binds the GHR complex and
promote its ubiquitination and subsequent proteasomal degra-
dation (Vesterlund et al., 2011). The phenotype of SOCS2 null
mice (SOCS2KO) identifies SOCS2 as the key physiological player
in the negative regulation of GH-dependent body growth (Hor-
vat and Medrano, 2001; Greenhalgh et al., 2005; Vesterlund et al.,
2011). Other studies have demonstrated that SOCS2 is essential
for the regulation of GH actions not directly related to somatic
growth. For example, SOCS2 can block GH-dependent inhibition
of neural stem cell differentiation. Consequently SOCS2KO mice
have fewer neurons in the developing cortex, whereas SOCS2 over-
expression results in increased neural differentiation. It has also
been demonstrated that SOCS2 inhibits intestinal epithelial pro-
liferation (Miller et al., 2004). Recently, we have identified SOCS2
as an important regulator of hepatic homeostasis (lipid and glu-
cose metabolism and inflammation) under conditions of high-fat
dietary stress (Zadjali et al., 2012). In addition to GHR down-
regulation, other mechanisms are needed to complete inactivation
of GH signaling. Since activation of GH-dependent signaling path-
ways is critically based on protein phosphorylation on tyrosine,
serine, or threonine residues, the obvious mechanism for deacti-
vation of this process is the action of protein phosphatases. First,
several studies have resulted in the identification of phosphatases
which are involved in the specific inactivation of GHR signaling.
Second, signal regulatory protein (SIRP)-α, which belongs to a
family of ubiquitously expressed transmembrane glycoproteins,
negatively regulates GH-activated signaling by inhibition of the
phosphorylation of JAK2, STAT5b, STAT3, and ERK1-2 but the
physiological relevance of this mechanism is uncertain (Stofega
et al., 1998).
STAT5B, A GH SIGNALING INTERMEDIATE REGULATING SOMATIC
GROWTH, LIPID METABOLISM, AND GENDER DIMORPHISM
Global expression analysis of GH actions in liver using microarrays
clearly indicates that most of the known physiological effects of GH
can be explained through its effects on the transcription of specific
genes (Flores-Morales et al., 2001; Tollet-Egnell et al., 2001; Wax-
man and O’Connor, 2006; Ceseña et al., 2007; Vidal et al., 2007).
To this end, GH is known to regulate a network of transcription
factors that include, among others, nuclear receptors/transcription
factors such as HNF (4α, 6, 3β), PPARα, CAR, FXR, SHP, SREBP,
CRBP, C/EBPβ, and STAT5b. Based on the analysis of liver tran-
script profiles from targeted disruption/mutation of signaling
components of GHR-signaling pathways or GHR itself, and GH
administration to GH-deficient (GHD) mice and rats, the main
metabolic process affected by GH status is energy/fuel metab-
olism, particularly lipid/fat metabolism. These findings in ani-
mals together with clinical studies of GH-insensitive subjects
have revealed the transcription factor STAT5b is a key GH sig-
naling intermediate for the regulation of target genes associated
with several liver physiological processes, including modulation
of body growth, cell cycle, and metabolism of lipids, bile acid,
steroids, and drugs (Baik et al., 2011). In addition,many transcripts
are regulated independently of STAT5b, presumably as a result
of GHR-dependent activation of ERK, Src, and PI3K signaling
pathways.
SOMATIC GROWTH
Growth hormone is predominantly linked to postnatal growth
(Butler and Le Roith, 2001). Liver is a major target tissue of GH and
the principal source of circulating IGF-I and the GH-dependent
transcription of IGF-I is directly regulated by STAT5 binding in
IGF-I gene promoter and enhancers (Ohlsson et al., 2009; Rotwein,
2012). Thus, both IGF-I and its transcriptional regulator STAT5
have key roles in mediating the actions of GH on body growth.
Importantly, intermittent (male pattern) GH administration to
rodents is a more potent stimulus of body growth rate, IGF-I
expression, and STAT5b nuclear translocation in liver than is con-
tinuous (female pattern) administration. This supports the notion
that larger body growth in male compared with female rodents
could be due to more effective stimulation of IGF-I and STAT5b
mediated transcription. IGF-I proteins are also induced by GH in
many tissues and local induction of IGF-I in chondrocytes plays an
important role in longitudinal growth. GH is, however, more effec-
tive than IGF-I because GH exerts additional growth-promoting
actions independent of IGF-I (Lupu et al., 2001). Importantly,
global disruption of STAT5b in mice causes loss of sexually dimor-
phic growth characteristics, so that the affected males reduced
their size to female size while female mice appeared unaffected
(Udy et al., 1997). Parallel observations were made with circu-
lating IGF-I, which is reduced by 30–50% in affected male mice,
but not in females. However, combined disruption of STAT5a/b
significantly reduced body weight gain in females and suppressed
body growth more than in STAT5b null male mice, approach-
ing that observed either GH or the GHR deficient mice (Rowland
et al., 2005). These studies demonstrated that STAT5b is important
for male-specific body growth, whereas STAT5a regulates body
growth in both sexes. Experiments in SOCS2KO mice also sup-
port that STAT5b is critical for GH-regulated somatic growth
in mammals (Greenhalgh et al., 2005). Importantly, SOCS2KO
mice have enhanced growth whereas combined STAT5bKO and
SOCS2KO mice do not, a demonstration that STAT5b is needed
for the excess of body growth observed in SOCS2KO mice. In addi-
tion to endocrine actions, paracrine involvement of STAT5a/b in
the effects of GH on muscle is also evident in the loss of muscle
IGF-I transcripts and mass seen with muscle-specific deletion of
Stat5a/b (Klover and Hennighausen, 2007). As mentioned above,
the growth of female STAT5bKO mice is normal whereas postna-
tal growth in female GHR-deleted mice is profoundly retarded.
These data suggest that in addition to STAT5b, other transcrip-
tions factors are related with growth. This is exemplified by the
glucocorticoid receptor (GR) which is a critical co-activator of
STAT5b in liver: near 25% of STAT5b-regulated hepatic genes are
regulated by a GR-STAT5b transcriptional complex (Mueller et al.,
2012). Importantly, these STAT5b and GR co-regulated transcripts
were preferentially enriched in functional groups related to growth
and maturation (i.e., IGF-I). Moreover, both direct and indi-
rect interactions between ER and STAT5 should be added to the
list of mechanisms regulated by nuclear receptors that modulate
GH-dependent transcription (Bjornstrom and Sjoberg, 2005).
LIPID AND GLUCOSE METABOLISM
Physiological effects of GH extend beyond the stimulation
of somatic growth. These include anabolic effects on protein
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synthesis and the regulation of lipid and glucose metabolisms
throughout life (LeRoith and Yakar, 2007). The key physiolog-
ical function of GH is the promotion of protein synthesis and
inhibition of protein degradation in muscle, bone, and other large
organs, inhibiting the catabolism of glucose and aminoacids by
promoting the utilization of lipids as energy source. These sys-
temic effects of GH are achieved through inhibition of insulin
actions and the promotion of FFA mobilization from adipose tis-
sue and liver (Lichanska and Waters, 2008; Vijayakumar et al.,
2010). The mechanisms of GH actions on lipid metabolism are
complex and involve both transcriptional and acute changes in
catalytic enzyme activities (Lichanska and Waters, 2008). It is well
established that human GH is a lipolytic hormone in adipose
tissue. One of the mechanisms by which GH leads to lipoly-
tic effects involve increased expression of β3-adrenergic recep-
tor in adipocytes followed by activation of hormone sensitive
lipase. Additional effects include uncoupling of the electron trans-
port chain which enhances mitochondrial heat generation at the
expense of energy production from ATP. Long-term administra-
tion of GH includes a decrease in fat deposition and an increase
in fat mobilization, increasing circulating FFA and glycerol levels.
GH reduces fat mass, particularly in individuals who have accu-
mulated excess fat during periods of GH deficiency. Obesity is
clinically evident in GHD patients, a decline in GH levels corre-
lates with age-related adiposity (Corpas et al., 1993) and lack of
GH or GH signaling induces obesity earlier in mice (Lichanska
and Waters, 2008). GHD in adulthood causes a syndrome char-
acterized by increased visceral adiposity, decreased muscle mass,
metabolic disturbances, and increase mortality associated with
cancer or vascular complications. This syndrome closely resembles
the metabolic syndrome and can be ameliorated by GH replace-
ment (LeRoith and Yakar, 2007; Lichanska and Waters, 2008).
In the skeletal muscle, GH can induce triglyceride (TG) uptake
by increasing lipoprotein lipase (LPL) activity and thereby pro-
moting lipid to be stored or utilized via lipid oxidation. Several
factors such as nutrition, exercise, and sex-steroid hormone sta-
tus can modify GH-induced TG storage and lipid oxidation in
skeletal muscle. In the liver, GH exerts a complex regulation of
lipid metabolism. GH can induce TG uptake, by increasing LPL
and/or hepatic lipase expression, and TG synthesis and secretion.
Data indicate that an ineffective GHR-JAK2-STAT5 signaling path-
way results in fatty liver in rodents which is due to enhanced
lipogenesis, increased FA uptake, and/or reduced TG secretion
(Cui et al., 2007; Fan et al., 2009; Barclay et al., 2011; Sos et al.,
2011). The fatty liver observed in mice with liver-specific dis-
ruption of JAK2 seems to be developed by both GH-dependent
increases in fat mobilization from adipocytes, increasing circu-
lating FFA, and increased hepatic uptake of FFA (Sos et al.,
2011). In previous studies with GH-treated hypophysectomized
rats we demonstrated that GH decreases PPARα expression and
lipid oxidation while increasing the expression of genes promot-
ing de novo lipid synthesis in liver (Flores-Morales et al., 2001).
Additional studies in bovine GH-transgenic (Olsson et al., 2003;
Wang et al., 2007) and dwarf (Stauber et al., 2005) mice, have all
revealed that GH down-regulates genes involved in lipid oxida-
tion and increases the expression of genes promoting lipogenesis
in the liver. In contrast, the ablation of SOCS2 in mice, which
increases STAT5 signaling, protects from high-fat diet-induced
liver steatosis (Zadjali et al., 2012). The deficiency of GHR-JAK2-
STAT5 signaling has also been studied by mutagenesis of GHR
in mice, a model that causes severe obesity in mature mice in
proportion to loss of STAT5b activity (Lichanska and Waters,
2008). These data have shown that STAT5 regulates several key
enzymes or genes otherwise involved in lipid and energy balance
and, based on altered transcript expression, several processes have
been implicated. For example, up-regulation of some lipogenic
genes (e.g., CD36, FAS, PPARγ, PGC1α/β, SCD1) may contribute
to increased hepatic lipid storage, steatosis, and adiposity in defi-
cient GHR-JAK2-STAT5 signaling models whereas expression of
antilipogenic genes such as FGF21 and INSIG2 are decreased.
These data have provided new insights into the long-known anti-
adiposity actions of GH and highlighted a key role for STAT5 in
these actions. This is supported by original findings that STAT5b-
deleted male mice become obese in later life (Udy et al., 1997)
and that STAT5b deletion in a mature human was associated
with obesity (Vidarsdottir et al., 2006). These findings highlight
two physiological aspects of GHR-STAT5 signaling: (1) the anti-
obesity actions of GH are enhanced by the pulsatility of GH
secretion evident in males because of pulsatile STAT5 activation
and (2) despite normal plasma FFA and minimal adiposity, absent
GHR activation lead to hepatic steatosis because of reduced STAT5
activation, which prevents this pathology (Lichanska and Waters,
2008).
In liver, GH has a stimulatory effect on glucose production
which may be a result of its antagonism of insulin action leading to
hepatic/systemic insulin resistance (Vijayakumar et al., 2010). GH
increases glucose production by increasing glycogenolysis; how-
ever, it has either a stimulatory or no effect on gluconeogenesis.
Over-expressing the human GH gene in rat increases basal hepatic
glucose uptake and glycogen content (Cho et al., 2006). In con-
trast, GHD mice (Ames) and the GHRKO mice have improved
insulin sensitivity and up-regulated hepatic insulin signaling, sug-
gesting that GH antagonizes insulin signaling locally in the liver
(Dominici and Turyn, 2002). GH-induced insulin resistance may
be developed by the increased FFA mobilization from adipose tis-
sue which can then affects liver insulin sensitivity, and lead to
insulin resistance and up-regulation of the PEPCK and G6Pase.
However, the LID mice (i.e., IGF-I specific liver deficient mice)
showed a 75% reduction in circulating IGF-I levels, threefold to
fourfold increase in circulating GH levels and insulin resistance,
without significant increase in circulating FFA levels, arguing for
the existence of a local crosstalk between GH and insulin sig-
naling systems within the hepatocyte. Moreover, while crossing
LID mice with GH transgenic mice, serum FFA levels were sig-
nificantly increased and there was an improvement in insulin
sensitivity during a hyperinsulinemic-euglycemic clamp due to
higher hepatic, adipose tissue, and skeletal muscle glucose uptake
(Yakar et al., 2004). This suggests that, in addition to FFA, other
factor(s) may also contribute to GH-induced insulin resistance.
A candidate is the SOCS family of proteins (e.g., SOCS3 and
SOCS2) whose expression is induced by both GH and insulin in
the liver (Rico-Bautista et al., 2006). However, we have recently
shown that deletion of SOCS2 protects against hepatic steato-
sis but worsen insulin resistance in high-fat diet-fed mice (Zadjali
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et al., 2012). Another mechanism by which GH may induce insulin
resistance is by increasing the expression of the p85, a regula-
tory subunit of the PI3K (LeRoith and Yakar, 2007). Finally, given
the large homologies between the insulin and IGF-I systems, it is
not surprising that IGF-I exerts profound effects on carbohydrate
metabolism. Alternatively, IGF-I may enhance insulin sensitivity
by suppressing GH release, via negative feedback. Therefore acti-
vation of IGF-I signaling adds more complexity for understanding
molecular mechanisms involved in GH-induced insulin resistance
in vivo.
GENDER DIMORPHISM
Sex hormones imprint a sex-dependent pattern of pituitary GH
hormone secretion which is a major player in establishing and
maintaining the sexual dimorphism of hepatic gene transcrip-
tion that emerges in rodents at puberty (Mode and Gustafsson,
2006). Genomic and bioinformatic analysis have contributed to
solve molecular mechanisms involved in GH-regulated hepatic
gene transcription (Flores-Morales et al., 2001; Tollet-Egnell et al.,
2004; Ståhlberg et al., 2005; Waxman and O’Connor, 2006; Wau-
thier et al., 2010). Sex-dependent expression and GH regulation
characterizes several families of hepatic genes involved in endo-
and xenobiotic metabolism as well as relevant metabolic functions
(e.g., lipid metabolism); 20–30% of all hepatic genes have a sex-
specific expression pattern in rodents. Most of these hepatic sex
differences are explained by the female-specific secretion pattern of
GH, through the induction of female-predominant transcripts and
suppression of male-predominant. A key player in this scenario
is STAT5b. Primary results from experiments with STAT5b null
mice indicated that STAT5b is responsible for the masculinization
of the male liver (Udy et al., 1997; Waxman and O’Connor, 2006).
STAT5b binding sites have been found in the promoter of sev-
eral sex-differentiated CYP genes in rat (e.g., Cyp2c12, Cyp2c11,
Cyp2a2). Conversely, other transcription factors (e.g., HNF6 and
HNF3b) are more efficiently activated in female liver or by the
continuous GH secretion pattern. HNF4 and HNF3b are relevant
transcription factors for regulating genes involved in glucose and
lipid metabolism (Wolfrum et al., 2004; Sampath and Ntambi,
2005) and most likely they also contribute to sexual dimorphism.
Continuous administration of GH has been shown to increase
hepatic expression of transcription factor SREBP-1c and its down-
stream target genes (Tollet-Egnell et al., 2001), as well as hepatic
TG synthesis and VLDL secretion (Sjoberg et al., 1996). As men-
tioned above, GH actions in liver lead to increased lipogenesis (i.e.,
induction of SREBP-1c) and decreased lipid oxidation (i.e., inhi-
bition of PPARα), and promoted anabolic growth in peripheral
tissues (i.e., muscle, bone) (Flores-Morales et al., 2001; Tollet-
Egnell et al., 2004; Ståhlberg et al., 2005). Relevant to this review,
estrogens cause opposite effects on lipid and glucose metabo-
lism which represents a relevant point of regulatory interactions
between estrogens and GH (see below).
THE LIVER, A PHYSIOLOGICAL TARGET FOR ESTROGENS
Estrogen signaling can be mediated by multiple receptors
(Heldring et al., 2007). Most of the known estrogenic effects are
mediated via direct interaction of estrogen with the DNA-binding
transcription factors, ERα and ERβ. Classical estrogen signaling
occurs through a direct binding of ER dimers to estrogen respon-
sive elements in the regulatory regions of estrogen target genes
followed by activation of the transcriptional machinery at the
transcription start site. In addition, estrogen can modulate gene
expression by a second mechanism in which ERs interact with
other transcription factors, like STAT5, through a process referred
to as transcription factor crosstalk. Estrogen may also elicit effects
through non-genomic mechanisms, which involve the activation
of downstream kinase pathways like PKA, PKC, and MAPK via
membrane-localized ERs. An orphan G protein-coupled receptor
(GPR)-30 in the cell membrane mediates non-genomic and rapid
estrogen signaling. Finally, E2 has a similar affinity for ERα and
ERβ and these receptors are activated by a wide range of ligands
including selective estrogen receptor modulators (SERMs) (e.g.,
raloxifene) as well as many other compounds. ERβ is expressed
in the ovary, prostate, lung, gastrointestinal tract, bladder, and
hematopoietic and the central nervous systems, while ERα is
mainly expressed in reproductive tissues, kidney, bone, white adi-
pose tissue, and liver. The liver expresses ERα but almost unde-
tectable levels of ERβ which indicates that specific actions of
estrogens in liver can be mimicked by using selective ERα ago-
nists such as propyl-pyrazole-triol (PPT) (Lundholm et al., 2008).
Collectively, the above mentioned data indicate that the mecha-
nisms involved in ER signaling are influenced by cell phenotype,
the target gene, and the activity or crosstalk with other signal-
ing networks. The liver represents a site where physiologically
and therapeutically relevant interactions between estrogens and
GH can be developed. Particularly relevant is the interaction of
estrogens with GHR-JAK2-STAT5 signaling pathway in the regu-
lation of somatic growth, lipid and glucose metabolism, and “liver
sexuality.”
SOMATIC GROWTH AND BODY COMPOSITION
It is well known that sex steroids and GH interact closely to reg-
ulate pubertal growth (Kerrigan and Rogol, 1992). Interestingly,
loss of ERα (ERαKO), but not ERβ, mediates important effects of
estrogen in the skeleton of male mice during growth and matu-
ration (Vidal et al., 2000). A phenotype like to ERαKO mice can
be found for aromatase-deficiency in mice or human, which are
deficient in estrogens (Riggs et al., 2002). In addition, gender-
related differences in body composition are in part mediated by
sex steroids modulating the GH-IGF-I axis (LeRoith, 2009; Rogol,
2010; Birzniece et al., 2011). This is supported by the observa-
tion of gender differences in body composition emerge at the time
of pubertal growth. Furthermore, the efficiency of GH activity is
also modulated by estrogens in adulthood. This is exemplified by
women being less responsive than men to GH treatment (Bur-
man et al., 1997); GH treatment induces a greater increase in lean
mass and decrease in fat mass, or a greater increase in indices
of bone turnover and in bone mass, in GHD male compared
to female patients. Relevant to GH physiology is the alteration
of IGF-I bioavailability by oral administration of pharmacolog-
ical doses of estrogens [reviewed by Leung et al., 2004]. IGF-I
tissue availability and activity are regulated by IGF binding pro-
teins (IGFBPs) (Kaplan and Cohen, 2007; LeRoith and Yakar, 2007;
Ohlsson et al., 2009). IGF-I circulates almost entirely as a ternary
complex bound to IGFBP-3 and the ALS both of which are strongly
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GH-regulated in liver. This ternary complex regulates the bioavail-
ability of IGF-I. IGFBP-1 is also a liver-derived protein that binds
the small fraction of free IGF-I and attenuates the hypoglycemic
effect of the growth factor (Lewitt et al., 1991). In contrast to its
suppressive effect on ALS and IGF-I, the oral administration of
estrogens increases circulating IGFBP-1. The effect of increased
IGFBP-1 can be predicted to reduce further the free fraction of
IGF-I, which would be expected to reduce its activity. Interestingly,
the activation of GH-STAT5b signaling induces the expression of
ALS and IGF-I but inhibits IGFBP-1 (Ono et al., 2007). Therefore,
the inhibition of GHR-JAK2-STAT5 signaling pathway in liver (see
below), most likely contributes to the effects of estrogens on IGF-
I, ALS, and IGFBP-1. Thus, estrogens exert profound effects on
liver-derived IGFPBs when administered by the oral route which
most likely modify the biological actions of IGF-I. In addition, oral
administration of pharmacological doses of estrogen can inhibit
GH-regulated metabolic effects (e.g., lipid oxidation, protein syn-
thesis) (Huang and O’Sullivan, 2009). These effects on metabolism
and body composition are attenuated by transdermal administra-
tion, suggesting that liver is the major site of regulatory control by
estrogen.
Estrogens can modulate GH actions on liver by modulat-
ing GH responsiveness, which include changes in hepatic GHR
expression and crosstalk with GH-activated JAK2-STAT5 signal-
ing pathway (Leung et al., 2004) (Figure 3). Particularly, E2
can induce SOCS2 and SOCS3 expression which in turn nega-
tively regulates GHR-JAK2-STAT5 signaling pathway leading to
reduction in transcriptional activity in liver. Therefore, beside E2
regulation of sex dimorphic pattern of pituitary GH secretion,
induction of SOCS expression, and inhibition of JAK2-STAT5 sig-
naling is a very relevant mechanism that, in part, could explain
how estrogens directly inhibit the effects of GH in several STAT5-
regulated actions (i.e., somatic growth, body composition, metab-
olism, and gender-related hepatic functions). We have observed
that long-term administration of physiological doses of E2 to
GHD male rats (hypothyroid) regulates several members of SOCS
family by a complex interplay with GH and thyroid hormones
(Santana-Farre et al., 2008). Hypothetically, other members of
the negative regulators of STAT family may also contribute to
estrogen interaction with GH signaling in liver. This is explained
by ERα stimulation of PIAS3 expression which binds to and
blocks STAT3 DNA-binding activity. Interestingly, E2 activation
of ER followed by direct interaction of ER with STAT5 may also
inhibit STAT5-dependent transcriptional activity (Faulds et al.,
2001; Wang et al., 2004). On the other hand, it has been shown
that E2 activation of ERα or ERβ, via non-genomic mechanisms,
induces STAT5 (and STAT3)-dependent transcriptional program
in endothelial cells (Bjornstrom and Sjoberg, 2005). Overall, these
studies have shown a direct interaction between ER and STAT5
signaling and also demonstrate that functional consequence of
this crosstalk depends on the precise milieu of the intracellular
environment.
LIPID AND GLUCOSE METABOLISM
Several studies have suggested that E2-mediated signaling can have
an important role in the control of lipid and glucose metabolism
(Barros and Gustafsson, 2011; Faulds et al., 2012). Studies in both
human and rodents suggest that altered levels of estrogen or its
receptors can lead to a metabolic syndrome-like phenotype (i.e.,
insulin resistance, adiposity, dyslipidemia). For example, post-
menopausal women are three times more likely to develop meta-
bolic syndrome associated abnormalities than premenopausal
FIGURE 3 | Schematic representation of signaling pathways activated by
E2 and its crosstalk with GH. Estradiol can regulate GH actions in liver by
modulating GH responsiveness which includes changes in hepatic GHR
expression and crosstalk with GH-activated JAK2-STAT5 signaling pathway.
Estrogens can induce SOCS2 expression which in turn negatively inhibits
GHR-JAK2-STAT5 signaling pathway.
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women (Eshtiaghi et al., 2010). Furthermore, estrogen/progestin
based hormone replacement therapy in postmenopausal women
has been shown to lower visceral adipose, fasting serum glucose,
and insulin levels (Munoz et al., 2002). Clinical observations in
ERα deficient male or with decreased levels of aromatase noted
the development of increased body weight, insulin resistance, and
hyperinsulinemia (Smith et al., 1994; Jones et al., 2007). Simi-
larly, the ERαKO and the aromatase deficient mice develop insulin
resistance, intra-abdominal adiposity, steatosis, and impaired lipid
oxidation in liver, which can be reverted by E2 treatment (Heine
et al., 2000; Simpson et al., 2005; Jones et al., 2007). The bene-
ficial influence of estrogen in relation to normalizing lipid and
glucose homeostasis is also evidenced in ob/ob and high-fat diet-
fed mice, models of obesity, and type 2 diabetes. In both models,
E2 treatment improves glucose tolerance and insulin sensitivity,
and reduce weight in high-fat diet-fed mice (Gao et al., 2006;
Bryzgalova et al., 2008). Studies in ERαKO mice have shown that
ERαmainly mediates beneficial metabolic effects of estrogens such
as anti-lipogenesis, improvement of insulin sensitivity and glu-
cose tolerance, and reduction of adiposity (Barros and Gustafsson,
2011; Faulds et al., 2012). In contrast, ERβKO mice do not exhibit
altered insulin sensitivity and/or alterations in body weight. How-
ever, some evidence exists that ERβ may be detrimental for the
maintenance of regular glucose and lipid homeostasis. In addi-
tion to the observations from ERαKO, selective ablations of ERα
in the hypothalamic brain region or the hematopoietic/myeloid
cells have both been reported to give rise to an increase in body
weight and reduced glucose tolerance (Ribas et al., 2011; Xu et al.,
2011). Insulin resistance in ERαKO mice is largely localized to the
liver, including increased lipid content and hepatic glucose pro-
duction. Surprisingly, the liver-selective ablation of ERα (LERKO)
did not recapitulate the observed ERαKO mice phenotype (Matic
et al., 2013). LERKO mice did not increase body weight nor
developed glucose intolerance or insulin resistance, even when
challenged with a high-fat diet. The authors suggest the presence
of unidentified compensatory mechanism/s or that hepatic insulin
resistance occurs as a secondary effect upon ablation of E2 sig-
naling in other cell types. Furthermore, treatment of ob/ob mice
with the ERα-selective agonist PPT can improve glucose toler-
ance and insulin sensitivity which supports the critical role of ERα
signaling in the control of glucose homeostasis. Estrogenic sig-
naling via GPR-30 has also been implicated in insulin production
and glucose homeostasis (Mårtensson et al., 2009). As mentioned
above, the absence of E2 or GHR-JAK2-STAT5 signaling causes
adiposity and hepatic steatosis which can be ameliorated by E2
(Heine et al., 2000; Simpson et al., 2005; Jones et al., 2007) or GH
(LeRoith and Yakar, 2007) replacement, respectively. This suggests
that E2 and GH signaling regulate overlapping cellular networks
related with physiological control of lipid and glucose metabolism
(Figure 4).
THE “LIVER SEXUALITY,” A PHENOTYPE REGULATED BY GH AND SEX
STEROIDS
As mentioned above, sex steroids are physiological regulators
of pituitary GH secretion and, indirectly, regulate sex-specific
liver physiology (Mode and Gustafsson, 2006). From neonatal
FIGURE 4 | Physiological effects of E2 and GH on lipid and glucose metabolism in liver.
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period of life, gonadal steroids play a critical role to main-
tain liver response to GH in adulthood. Neonatal exposure to
androgens is crucial and the full response to androgens in adult-
hood is dependent on neonatal imprinting by androgens. The
male characteristic metabolism in liver in adulthood is depen-
dent on continuous androgen exposure. In female rats, gonadec-
tomy has little impact on hepatic steroid metabolism; estro-
gen treatment, however, feminizes hepatic metabolism in male
rats. Genome-wide screens of gene expression have shown that
GH- and sex-dependent regulation of hepatic gene expression is
not confined to steroid or drug metabolism. Moreover, a num-
ber of other hepatic genes have been found to be up- and/or
down-regulated by the different patterns of GH or sex-steroid
exposure. GH- and sex-dependent hepatic transcripts encoding
plasma proteins, enzymes, transcription factors, and receptors
involved in the metabolism of proteins, carbohydrates, lipids, or
signaling regulation have been identified (Flores-Morales et al.,
2001; Ståhlberg et al., 2005; Waxman and Holloway, 2009). A
consensus exists that the response to sex-different GH patterns
is the major cause of gender dimorphism in liver; however,
it is likely that factors other than the sexually dimorphic pat-
tern of GH secretion are behind some sex differences in rat
liver. Potential mechanisms that could contribute to “liver sex-
uality” are the pituitary-independent effects of estrogens through
interaction with ERα or GH-JAK2-STAT5 signaling pathway in
liver.
CONCLUSION
Growth hormone and E2 are critical regulators of body growth
and composition, somatic development, metabolism, and gen-
der dimorphism. GH and E2 signaling play a critical role
in liver physiology and pathology in both female and male.
Physiologically and therapeutically relevant are E2 interactions
with GH-regulated endocrine (e.g., IGF-I), metabolic (e.g., lipid
and glucose metabolism), and sex-differentiated (e.g., endo-
and xenobiotic metabolism) functions in liver. The influence
of estrogens is executed at the level of pituitary GH secre-
tion and the regulation of GHR-JAK2-STAT5-SOCS signaling
pathway. Therefore, the complex estrogen/GH interplay is rel-
evant because physiological roles that these hormones have in
mammals, and the widespread use of estrogen-related com-
pounds. In the general population, the endocrine and meta-
bolic consequences of long-term exposition to estrogens or
novel estrogen-related compounds and their influence on the
GH axis are largely unknown. Understanding this complex
interaction in physiological and pathological states could con-
tribute to prevent health damage and improve clinical manage-
ment of patients with growth, developmental, and metabolic
disorders.
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